Vistagen Therapeutics (VTGN) Free Cash Flow (2017 - 2025)
Historic Free Cash Flow for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$17.7 million.
- Vistagen Therapeutics' Free Cash Flow fell 7176.07% to -$17.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$60.3 million, marking a year-over-year decrease of 5426.64%. This contributed to the annual value of -$42.1 million for FY2025, which is 6291.31% down from last year.
- As of Q4 2025, Vistagen Therapeutics' Free Cash Flow stood at -$17.7 million, which was down 7176.07% from -$13.8 million recorded in Q3 2025.
- Vistagen Therapeutics' Free Cash Flow's 5-year high stood at -$4.8 million during Q4 2023, with a 5-year trough of -$18.9 million in Q2 2025.
- In the last 5 years, Vistagen Therapeutics' Free Cash Flow had a median value of -$10.6 million in 2024 and averaged -$11.3 million.
- As far as peak fluctuations go, Vistagen Therapeutics' Free Cash Flow plummeted by 83715.95% in 2021, and later skyrocketed by 6217.58% in 2023.
- Quarter analysis of 5 years shows Vistagen Therapeutics' Free Cash Flow stood at -$12.0 million in 2021, then grew by 19.19% to -$9.7 million in 2022, then skyrocketed by 50.9% to -$4.8 million in 2023, then tumbled by 115.11% to -$10.3 million in 2024, then crashed by 71.76% to -$17.7 million in 2025.
- Its Free Cash Flow stands at -$17.7 million for Q4 2025, versus -$13.8 million for Q3 2025 and -$18.9 million for Q2 2025.